Ipamorelin doses, routes, and half-life — as the studies recorded them

Read this first

This page reports the doses and routes ipamorelin was studied at, in the species and settings where they appear in the literature. It is not a how-to. There is no validated human ipamorelin dose, because the one human efficacy trial failed and no dosing was ever approved ^[3]. Everything below is written as "in this study, this species received this amount by this route," and the popular CJC-1295 stack protocols are described as community practice with no peer-reviewed human basis. Two numbers anchor the page: ipamorelin's terminal half-life in people is about 2 hours ^[2], and the GH it triggers arrives as a single pulse peaking near 40 minutes after dosing ^[2]. Those facts shape why the compound is dosed the way it is in studies — and why claims of a fixed "correct" human dose are not supported by the evidence.

Doses used in the studies

Across the published record, ipamorelin appears at the following study doses, by species and route:

• Human PK/PD study: 4.21–140.45 nmol/kg IV over 15 minutes, single doses ^[2].
• Human Phase 2 ileus RCT: 0.03 mg/kg IV twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 micrograms/day subcutaneously, divided three times daily for 15 days ^[4].
• Ferret cachexia study (2024): 1–3 mg/kg intraperitoneally ^[5].

In the rat bone study, the effect was dose-dependent across that 18–450 microgram/day range, with the highest dose producing the largest bone-growth rate ^[4]. None of these regimens maps to a community subcutaneous protocol, and none establishes a human dose.

Half-life, routes, and handling

Ipamorelin's terminal half-life in healthy human volunteers is approximately 2 hours, with clearance 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The GH response is a single discrete pulse peaking around 40 minutes (0.67 h) post-dose, not a sustained elevation ^[2]. Routes studied include intravenous (human PK and clinical trials; rodent efficacy), subcutaneous (rodent bone and body-composition work, and the dominant route in community use), intranasal (rodent PK, ~20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Ipamorelin itself is not orally bioavailable; only engineered ipamorelin-derived analogs reach meaningful oral exposure. As a peptide, it is supplied lyophilized (freeze-dried) and is degraded by heat and repeated freeze-thaw — general research-handling observations, not a clinical preparation instruction.

How much CJC-1295 ipamorelin should I take

How much CJC-1295 ipamorelin should I take is the most common dosing question, and the honest answer is that no peer-reviewed human protocol exists for the combination. The community subcutaneous regimens that pair ipamorelin with CJC-1295 are anecdotal: they are not derived from any controlled human trial of the two peptides together, and this site does not provide them ^[3]. What the literature does establish is single-agent pharmacology — ipamorelin's ~2-hour half-life and 40-minute GH pulse ^[2], and CJC-1295's multi-day GH elevation after a single subcutaneous dose in healthy adults ^[11]. A research reader can understand why the two are paired without any number being presented as a personal dose.

How to reconstitute CJC-1295 ipamorelin 5mg

How to reconstitute CJC-1295 ipamorelin 5mg is a handling question that the research-supply literature addresses only in general terms, and one this site treats as laboratory handling rather than preparation for use. Lyophilized peptide is typically dissolved with bacteriostatic water for research handling, then kept refrigerated because peptides degrade with heat and repeated freeze-thaw cycles. These are general stability observations drawn from the research-supply context ^[2]. No volume, concentration, or administration instruction is provided here, and none should be inferred — there is no approved human ipamorelin preparation, alone or combined with CJC-1295.